home
portfolio
approach
team
careers
news
contact
investor portal
home
portfolio
approach
team
careers
news
contact
investor portal
Nextech Invest
Kura Oncology Provides Update on Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
Kura Oncology Provides Update on Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
Post navigation
Previous Post
Previous
Blueprint Medicines to Report Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 21, 2018
Next Post
Next
Blueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial Results